Ibogaine by David Dardashti Explores Groundbreaking Research Linking Genetic Enhancers to Neurological Disease Treatment, Including Parkinson's
The study utilized advanced genomic techniques, including CAGE, NET-CAGE, and Capture Hi-C/HiCap, to identify and characterize thousands of enhancers – non-coding DNA regions that play a crucial role in gene regulation – active during neuronal differentiation. Crucially, the researchers discovered a significant enrichment of genetic variants (SNPs) associated with Parkinson's disease and schizophrenia within these enhancers. This finding suggests that these enhancers, and the genes they regulate, are directly implicated in the development and progression of these conditions.
David Dardashti, a prominent advocate for ibogaine research, recognizes the profound implications of this study for the field of ibogaine therapy. "This research provides a critical piece of the puzzle in understanding how ibogaine may exert its remarkable effects," Dardashti explains. "By demonstrating the direct involvement of specific genetic enhancers in neurological disorders, it opens up exciting new avenues for exploring ibogaine's mechanism of action at a molecular level."
Ibogaine has shown promise in anecdotal reports and preliminary studies for its ability to alleviate symptoms of neurological conditions, including addiction, and potentially Parkinson's. Its purported anti-aging and restorative properties have also garnered significant interest. While the exact mechanisms remain under investigation, one hypothesis centers on ibogaine's potential to influence gene expression, possibly through interactions with these very enhancers identified in the EMBO Reports study.
The study's focus on LUHMES cells, a model for human dopaminergic neurons (the cells primarily affected in Parkinson's disease), is particularly relevant. By linking specific enhancers to genes involved in neuronal differentiation and disorders, the research provides a potential roadmap for understanding how ibogaine might influence these crucial cellular processes.
Dardashti is particularly intrigued by the potential connection between the identified genetic enhancers and the "genetic rejuvenating factors" hypothesized to be influenced by ibogaine. "If ibogaine can modulate the activity of these enhancers, which are clearly linked to neurological health and disease, it could explain its reported ability to promote neuroplasticity, reduce neuroinflammation, and potentially even reverse some of the cellular damage associated with conditions like Parkinson's," he notes.
The research highlights the "vast regulatory potential embedded in non-coding regions" of the genome. This aligns with the emerging understanding of ibogaine's potential to induce broad-spectrum changes in gene expression, leading to long-lasting therapeutic effects.
Ibogaine by David Dardashti is committed to rigorously examining the findings of this and other related studies. This deeper dive will help determine, specifically the implications for ibogaine treatment protocols and future research directions. The goal is to move beyond anecdotal evidence and establish a solid scientific foundation for ibogaine's use in treating neurological disorders, including the potential for mitigating the progression of Parkinson's disease.
About Ibogaine by David Dardashti:
Ibogaine by David Dardashti is dedicated to exploring the therapeutic potential of ibogaine and promoting responsible research into its applications for addiction, neurological disorders, and overall well-being.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Calgary Herald
07-08-2025
- Calgary Herald
Parkinson Canada Cycling challenge passing through Calgary
Article content Parkinson Canada will be hosting a peloton across Canada with their Spinning Wheels Tour, which plans to roll by Calgary on Aug. 13. Article content The two-month cycling journey will host around 250 cyclists over three teams that will travel across Canada. The goal is to raise awareness and $200,000 for Canadians with Parkinson's disease. Article content Article content In Canada, there are more than 110,000 individuals who live with Parkinson's. Article content Senior director of events, stewardship and partnerships for Parkinson Canada,, said that this will their third year bringing this event across the nation. Article content 'This all started with three gentlemen with Parkinson's who decided to cycle across Canada to raise awareness about Parkinson's and build community across the country,' McMillan said. Article content The original concept aimed to reach major urban cities, rural areas, and northern communities to connect with as many people as possible. Article content Article content View this post on Instagram A post shared by Parkinson Association Alberta (@parkinsonassociationofalberta) Article content 'In the tours, they cycle around the province and connect with us at Parkinson Canada, local Parkinson's organizations and provincial ones, just to promote what they are doing as much as possible, to raise awareness and build those connections,' he said. Article content Article content An added benefit of the tour demonstrates the benefit of cycling for symptom alleviation for people who live with Parkinson's. Article content 'You don't need to ride 100 km every day, but just getting out there and riding five, 10, or even 15 km a day or whatever you can manage really does help with the symptoms of Parkinson's,' he said. The tour also raises money for local and provincial Parkinson's organizations, alongside Parkinson Canada. Article content 'Any money that is raised through that goes directly back into the community, to support the people and programs for people living with Parkinson's,' McMillan said. Article content Article content Rider and co-chair for the Spinning Wheels Tour, Lloyd Taylor, was diagnosed with Parkinson's at the age of 53. Article content Five years later, cycling came to his rescue after being introduced to it through a local cycling group. Article content 'I thought that it's not possible since I have a tremor, so I'd be like an egg on a spoon and I'd just fall off,' Taylor said. 'I did have some falls, but I was amazed at the impact of cycling on the symptoms, and it's something that I've heard over and over. Article content 'The tremor that I have constantly spilling soup and knocking over coffee cups is soothed on the bike, it almost disappears. It's so freeing to be on the bike.' Article content At the time of his interview with Postmedia, Taylor and his fellow riders were sheltering from the rain in Vancouver. Their goal is to ride to Calgary through Lundbrek, cycle to Edmonton, then make their way to Saskatchewan. Article content 'I'm really excited to head into Calgary,' Taylor said. 'I'm told the ride into Calgary is gorgeous, and there's a Parkinson's group in Alberta that is going to host us upon our arrival and throw a meet-and-greet, so I'm really looking forward to meeting them and seeing Calgary.'
Global News
06-08-2025
- Global News
MS could start up to 15 years earlier than thought, new UBC research suggests
Could doctors of the future one day spot the signs of multiple sclerosis (MS) years earlier than they do now? It's an intriguing possibility raised by new research from the University of British Columbia, which suggests the disease's earliest warning signs may materialize up to 15 years before the first classical neurological symptoms do. 'This is really important,' said senior author and UBC neurology Prof. Dr. Helen Tremlett. 'If you want to prevent MS from occurring at all, if you want to know what causes multiple sclerosis … we need to now make sure that we look much further back in time to avoid thinking that something causes MS when, in actual fact, the disease has already started.' 5:50 Cyclist Embarks on Cross-Canada Journey to Raise Awareness for Multiple Sclerosis The study, published Tuesday in the journal JAMA Network Open, came to its conclusions by analyzing the health records of more than 12,000 British Columbians. Story continues below advertisement Researchers found that patients who developed MS actually began accessing health care at a higher rate than the general population a decade and a half before their classic MS symptoms appeared. Researchers looked at doctor visits going 25 years before MS patients' symptom onset, more than double the range that prior studies have examined. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Tremlett said the research suggests the existence of a 'prodromal phase' to MS — a period during which non-specific signs and symptoms occur before the classical onset of disease. 'Historically, MS wasn't thought to have a prodromal phase, which is a shame because other neurological conditions like Parkinson's, this concept of a prodromal phase they've been studying since the 1980s,' she said. 'They can see that before the classical onset of Parkinson's motor symptoms, maybe a decade or so before, they can pick up this prodromal phase. So I think it's super exciting that we're starting to realize this happens in multiple sclerosis as well.' 2:19 A day in the life of someone living with multiple sclerosis By studying the health records, Tremlett's team found a steady build-up in contact with the health-care system leading up to patients' MS diagnosis, with different types of doctor visits increasing at distinct points in time. Story continues below advertisement At 15 years before MS symptoms, they picked up a general increase in doctor's visits, particularly related to symptoms like fatigue, pain, dizziness and mental health conditions like depression and anxiety. At 12 years prior, they found an uptick in visits to a psychiatrist. Eight to nine years prior, visits to ophthalmologists and neurologists increased, potentially pointing to blurry vision or eye pain. Visits to the emergency room and radiology increase three to five years before MS symptom onset. And in the year before classic symptoms appeared, doctors' visits across a slew of specialties picked up, including neurology, emergency medicine and radiology. 1:38 Time spent in Canada increases MS risk for immigrants: study While that information gives researchers more threads to tug on, Tremlett stressed that these general symptoms cannot be used to diagnose MS, and that most people who experience them have nothing to worry about. Story continues below advertisement 'It's important for listeners to know that what we're looking at here is patterns of health-care use in large groups of people,' she said. 'The vast majority of people who visit a doctor for the issues I mentioned do not, and will not, develop multiple sclerosis. So I do not want anyone to feel alarmed or concerned by our findings.' However, she said the research suggests there is an opportunity in the future to recognize and potentially diagnose MS earlier, potentially through a biological marker in the blood, through family history or other combinations of clues that show someone to be in the disease's prodromal phase. Future research that achieves that goal, she said, could one day allow doctors to prevent or slow the disease's progression over the long-term. 'What I'm painting here is a picture that could be achievable in the future,' she said. 'But we're excited and we think that our findings kind of open that door to this new possibility.'
Globe and Mail
04-08-2025
- Globe and Mail
Ibogaine by David Dardashti Warns of Kratom's ‘Gateway' Dangers, Citing Alarming Trend in Patient Addiction Cases
WESTCHESTER, FL - August 4, 2025 - As the FDA intensifies its crackdown on the potent kratom compound 7-hydroxymitragynine (7-OH), the addiction treatment center Ibogaine by David Dardashti is issuing a critical warning based on alarming clinical trends. The clinic's founder, David Dardashti, is speaking out about the substance's deceptive role as a gateway to more dangerous opioids, based on a sharp increase in patients seeking treatment for kratom dependency at his facility. The recent FDA actions targeting concentrated 7-OH products—dubbed 'legal morphine' by some researchers—underscore a danger the clinical team at Ibogaine by David Dardashti sees daily. The clinic has witnessed a significant increase in patients arriving with a primary or secondary addiction to kratom, often after being misled by marketing that promotes it as a safe, herbal alternative to opioids. This firsthand clinical data forms the basis for their urgent public warning. 'We are seeing a disturbing pattern,' states David Dardashti. 'Patients come to us after starting with kratom, thinking it's a safe, natural remedy. They don't realize they are developing a true opioid dependency until it's too late. The initial effects fade, tolerance builds, and suddenly they are facing a full-blown addiction with severe withdrawals. The next logical step for many is to seek out something stronger and deadlier, like fentanyl. We are on the front lines of this trend, and it is alarming.' As referenced in recent reports, experts confirm that while the kratom leaf itself may be mild, concentrated extracts containing 7-OH are significantly more potent and act as pure opioids. This creates the dangerous cycle of dependency that the clinic observes. Users require ever-increasing doses, eventually finding that the legal substance no longer satisfies the addiction it created, driving them toward the illicit drug market. Despite the alarming trend, the team at Ibogaine by David Dardashti reports significant success in treating kratom addiction and offers a message of hope. Based on extensive clinical experience, the center has found a notable distinction in the recovery process for these patients. 'The good news in this growing crisis is that we've found that individuals dependent on kratom can be brought back to sobriety with less difficulty than those entrenched in long-term Suboxone or fentanyl use,' Dardashti explains. 'Ibogaine therapy works to reset the brain's neurotransmitters and interrupt addiction at the source. For our kratom patients, the process is often smoother and the path to a full recovery is remarkably clear. Our goal is to intervene effectively before the addiction escalates into a far more tragic story.' About Ibogaine by David Dardashti: Ibogaine by David Dardashti is a leading treatment center dedicated to helping individuals overcome chemical dependency through a unique combination of ibogaine therapy and holistic care. Founded by David Dardashti, the clinic leverages extensive clinical experience to provide a safe, medically supervised environment for profound psycho-spiritual healing and neurological reset, offering a definitive interruption to the cycle of addiction.
